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Abstract
Activated partial thromboplastin time (aPTT) is an important routine measure of intrinsic blood
coagulation. Addition of activated protein C (APC) to the aPTT test to produce a ratio, provides
one measure of APC resistance. The associations of some genetic mutations (eg factor V Leiden)
with these measures are established, but associations of other genetic variations remain to be
established. The objective of this work was to test for association between genetic variants and
blood coagulation using a high density genotyping array. Genetic association with aPTT and APC
resistance was analysed using a focused genotyping array that tests approximately 50,000 single
nucleotide polymorphisms (SNPs) in nearly 2000 cardiovascular candidate genes, including
coagulation pathway genes. Analyses were conducted on 2544 European origin women from the
British Women’s Heart and Health Study. We confirm associations with aPTT at the F12/GRK6
and KNG1/HRG loci, and identify novel SNPs at the ABO locus and novel locus KLKB1/F11. In
addition, we confirm association between APC resistance and factor V Leiden mutation, and
identify novel SNP associations with APC resistance in the HRG and F5/SLC19A2 regions. In
conclusion, variation at several genetic loci influences intrinsic blood coagulation as measured by
both aPTT and APC resistance.
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Introduction
Blood coagulation is an important process in preventing blood loss from damaged vessels,
but can also be responsible for thrombosis leading to ischaemic heart disease, stroke or
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venous thromboembolism1. An informative measure of efficacy of the intrinsic coagulation
pathway is activated partial thromboplastin time (aPTT), measured as time taken for a clot to
form in plasma in the absence of tissue factor following introduction of an activator (eg
silica). An abnormally short aPTT can indicate a hypercoaguable state in acute coronary
syndromes2, and is associated with increased risk of venous thrombosis3–5, whilst
abnormally long aPTT may also indicate thrombotic risk in the case of the lupus
anticoagulant6. Addition of activated protein C (APC), which deactivates factors Va and
VIIIa, and calculation of an APC resistance provides one measure of APC resistance 7,
including effects of factor V Leiden mutation as its major determinant8,9. There is evidence
to suggest aPTT is highly heritable10, thus meriting investigation of its genetic basis, but to
date the only high-density genetic association study of aPTT was a recently reported
genome-wide association study (GWAS) of aPTT in 1477 subjects from the Lothian Birth
Cohorts, which identified three novel loci associated with aPTT, namely: coagulation factor
XII (F12), kininogen 1 (KNG1), and histidine-rich glycoprotein (HRG)11. The IL3581Thr
variant in KNG1 has since been found to associate with risk of venous thrombosis as well as
aPTT12. No genome-wide association studies has been reported for APC resistance.
Materials and Methods
Subjects were from the British Women’s Heart and Health Study (BWHHS), a prospective
cohort study of heart disease in British women. Baseline recruitment was 1999-2001 (age
60-79 years), with blood samples for DNA, APC ratio and aPTT measurement taken from
consenting individuals. Protocols and consents were approved by relevant research ethics
committees13. aPTT measurements were available on 2962 women (mean age 68.8 years,
SD 5.5), and APC resistance on 2953 women (mean age 68.8 years, SD 5.5). Data are not
available where either insufficient blood was available to assay, consent was not given, or
assays failed in the laboratory.
DNA was extracted from whole blood using a salting-out procedure14. Genotyping was
successfully performed on 3445 of 3838 available samples using the Illumina HumanCVD
Beadchip15. Principal components analysis was used to check self-reported ancestry, with
32 individuals excluded to avoid stratification issues, leaving 3413 samples for analysis.
aPTT and APC resistance were assayed in an automated coagulometer (MDA-180, Organon
Teknika, Cambridge, UK) using reagents and standards from the manufacturer as previously
described16. APC ratio was assayed without factor V deficient plasma. Citrated plasma
samples were stored at −80°C for a maximum of 12 months prior to assay. Genotype and
phenotype data were available on 2618 women for aPTT (mean age 68.9 years, SD 5.5) and
2610 women for APC resistance (mean age 68.9 years, SD 5.5).
Analysis of genetic association was performed using linear regression without covariables
(adjustment for age had little effect; whilst clotting phenotypes are age dependent this cohort
are all post-menopausal and within the relatively narrow age-range 60-79 years.) using
PLINK17. SNPs out of Hardy-Weinberg equilibrium (p < 0.0001) were excluded, as were
any with a minor allele frequency below 0.1%, leaving 36,529 SNPs for analysis. Both traits
were natural log transformed, outliers greater than 2.5 standard deviations from the mean
were removed (on the basis that extreme values may represent either technical errors or
biological abnormalities unrelated to common polymorphic variants which are the focus of
our analyses), and warfarin users excluded, leaving 2510 participants with non-missing data
for aPTT (arithmetic mean 30.06 seconds, SD 1.103 seconds) and 2500 with non-missing
data for APC resistance (arithmetic mean 2.924, SD 1.134). Exclusion of women on
hormone replacement therapy (HRT, shown to associate with these measures16) was
evaluated, but did not substantially change the results. A stringent (given non-independence
of many SNPs) Bonferroni correction for 36,529 tests gives a threshold of p = 1.37×10−6 as
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equivalent to a single-test p = 0.05. Variable selection was performed in R using Akaike
Information Criterion (AIC)18 with the stepAIC function of the “MASS” library.
Results
Results of the HumanCVD BeadArray-wide association analysis with aPTT and APC
resistance are presented in table 1, with results of variable selection presented in table 2. The
SNPs most significantly associated with aPTT are in or near the F12 gene on chromosome 5.
The top SNP rs2545801 is a non-coding SNP upstream of F12, p = 1.39 × 10−59), with an
(antilogged) per-allele effect of 1.05 seconds on aPTT (95% CI 1.04-1.06). Other gene
regions showing association include the HRG/KNG1 region on chromosome 3 (top hit SNP
rs710446, p = 2.68 × 10−19), the ABO blood group (ABO) locus on chromosome 9
(rs657152, p = 2.45 × 10−11) and the kallikrein B (KLKB1) region on chromosome 4
(rs4253304, p = 1.67 × 10−7). Variable selection identified multiple statistically independent
signals at each locus except KLKB1 (table 2).
Table 1 also presents genetic association results for APC resistance. The most strongly
associated SNP with APC resistance is the factor V Leiden mutation (rs6025, p = 4.2 ×
10−104) in the factor V (F5) gene on chromosome 1. The other region associated with APC
resistance is the HRG region on chromosome 3 (top SNP rs16860992, p = 2.29 × 10−15).
Variable selection (table 2) suggests that all association with APC resistance in the F5 and
solute carrier family 19 member 2 (SLC19A2) region on chromosome 1 is attributable to the
functional factor V Leiden mutation, with no evidence of statistically independent effects for
other SNPs. In the HRG region on chromosome 3 there are three potentially independent
SNPs.
Discussion
Whilst the HumanCVD array is a candidate gene array, the coagulation pathway is well
represented, with SNPs in the genes for the majority of intrinsic and extrinsic pathway
proteins (table 3). We confirmed previous reports11 of effects in F12 (our “top hit”
rs2545801 is the best HumanCVD tag of rs2731672, HapMap r2 = 0.935 19), KNG1 (“top
hit” rs710446) and HRG (rs9898, significantly associated, but not our top hit at this locus).
We also found positive associations with aPTT at the G protein-coupled receptor kinase 6
(GRK6) gene, genomically adjacent to the F12 gene, although low LD between the “top hit”
SNPs at each locus suggests that these are marking independent effects (even if both the
effects are actually in the F12 gene). GRK6 (G protein-coupled receptor kinase 6)
deactivates G protein-coupled receptors, and thus may potentially also have a biological
effect in the clotting mechanism. The results of variable selection suggest that there may be
more than one causal site at each of the three main loci (excluding KLKB1).
We also found significant associations between aPTT and SNPs at the ABO and KLKB1
loci. Blood group O versus non-O becomes associated with lower levels of factor VIII and
von Willebrand factor (vWF) during childhood20 and continues into adulthood 21. Assuming
this relationship is causal, and given that aPTT is prolonged with both severe von
Willebrand Disease (vWF deficiency in type 1 and 3) and Hemophilia A (factor VIII
deficiency), we hypothesize that ABO genotype could associate with aPTT through
alteration of levels of vWF or factor VIII. There is also a previous report describing
association of ABO OO genotype with aPTT using a combined linkage and association
approach22. Our highest ABO locus association is with rs657152, which is in high linkage
disequilibrium (LD, r2=0.98)23 with rs8176719 (the O/non-O variant), and thus rs657152
closely marks the association of O blood group with clotting. SNP rs657152 is also in high
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LD (r2=0.93) with the myocardial infarction risk SNP reported by Reilly et al24, and hence
likely to tag the functional mechanism of that risk. KLKB1 encodes plasma kallikrein B
(Fletcher factor) 1, a glycoprotein which is involved in the intrinsic coagulation pathway25,
and also neighbours the F11 locus, encoding the factor XI protein, an important factor in the
intrinsic coagulation pathway.
We also present results for genetic associations with APC resistance. The HumanCVD array
directly assays the factor V Leiden mutation (rs6025), which is known to influence the APC
resistance26. This mutation shows the strongest genetic association with APC resistance in
our dataset (p = 4.2 × 10−104). Although our other association signals in the F5 gene are with
SNPs in little LD with rs6025 (eg r2 = 0.104), the magnitude of signal with rs6025 and
results of variable selection (table 2) suggest these SNPs are simply showing a “bystander”
effect. The other locus containing SNPs associating with APC resistance is HRG (same
SNPs as with aPTT, and showing consistent direction of effect on both tests). HRG
(histidine-rich glycoprotein) has a complex role in coagulation, with both anticoagulant and
antifibrinolytic properties reported 27,28. In our data we observe concordant effects of HRG
genotype on both aPTT (clotting speed) and APC resistance (response to inhibition). Whilst
there is a SNP in SLC19A2 (the gene for solute carrier family 19 (thiamine transporter),
member 2) this is physically close to the F5 gene on chromosome 1, so may simply tag
functional variation in F5. Although variable selection excludes the SLC19A2 SNP (table
2), the LD between all our top hits in F5 (including rs6025) and the SLC19A2 SNP is very
low (r2 < 0.006), suggesting this may either mark an independent effect in the F5 gene, or a
biological relevance of thiamine transport in coagulation.
With the exception of the factor V Leiden mutation (rs6025), already known to influence
APC resistance26, the majority of these results represent relatively small genetic effects on
aPTT and APC resistance. They therefore have very limited predictive value (especially as
individual variants), but instead offer additional insight into the functional pathways
underlying blood coagulation.
Our study has three principal limitations: (i) The HumanCVD array is not “genome-wide”.
Although even genome-wide arrays do not capture all genetic variation they offer a
relatively unbiased representation of the genome. Table 3 illustrates the extent to which this
candidate gene array represents coagulation system genes. (ii) The population we have
analysed is female, of European ancestry, and represents a fairly narrow age-range (post-
menopausal, 60-79 years). The results may therefore not be generalisable to other ancestries,
males or younger people. Further studies are needed to examine the associations of newly
identified genotypes with risk of venous and arterial thrombosis. (iii) These phenotypes (in
particular APC resistance) are infrequently measured on a cohort scale, and we were unable
to identify a suitable replication cohort with both these measures and appropriate genotyping
data. Appropriate caution should therefore be applied in interpreting results close to our
significance threshold. Our replication of published aPTT GWAS results11 and the very
strong statistical evidence (most of our reported p-values several orders of magnitude below
the nominal HumanCVD significance threshold of 1×10−6) support the reliability of these
findings.
In conclusion, we have both confirmed previous reports that F12/GRK6, KNG1 and HRG
are associated with aPTT11 and identified new SNPs at ABO and new genomic locus
KLKB1 associated with aPTT. We also present the first high-density genetic association
analysis of APC resistance, and identify signals in the F5 and HRG genomic regions. Our
findings suggest that KLKB1 and HRG may play potentially important roles in blood
coagulation.
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Table 3
Representation of coagulation factor genes on the HumanCVD array.
Coagulation Factor Gene symbol Number of SNPs
Fibrinogen FGA 23
Fibrinogen FGB 28
Fibrinogen FGG 20
Prothrombin F2 36
Tissue Factor F3 38
Factor V F5 126
Factor VII F7 34
Factor VIII F8 19
Factor IX F9 18
Factor X F10 20
Factor XI F11 20
Factor XII F12 19
Factor XIII F13A1 133
Factor XIII F13B 9
Von Willebrand Factor VWF 128
Prekallikrein KLKB1 21
Fibronectin FN 0
Antithrombin III SERPINC1 9
Heparin cofactor II SERPIND1 5
Protein C PROC 8
Protein S PROS1 8
Protein Z PROZ 6
Protein Z-related protease inhibitor (ZPI) SERPINA10 11
Plasminogen PLG 35
Alpha 2-antiplasmin SERPINF2 7
Tissue Plasminogen Activator PLAT 19
Plasminogen Activator PLAU 6
Plasminogen Activator Inhibitor-1 SERPINE1 33
Plasminogen Activator Inhibitor-2 SERPINB2 16
For each of the main proteins in the coagulation cascade the corresponding gene(s) is/are shown, along with the number of SNPs included in the
HumanCVD array for that gene.
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